(2S)-2-[[4-[(2-methyl-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[4-[(2-methyl-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
• 化学式: C₂₀H₂₀N₆O₆
• 分子量: 440.4
• InChiKey: FAFUUGXPENSZMV-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  183
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• COMPOUNDS AND COMPOSITIONS FOR USE IN THE TREATMENT AND PREVENTION OF LUNG AND BRAIN CANCER AND PRECANCEROUS CONDITIONS THEREOF
  申请人：Medicon Pharmaceuticals, Inc.

  公开号：US20140178461A1

  公开（公告）日：2014-06-26

  Novel compounds and pharmaceutical compositions thereof administered by the respiratory route for prevention and/or treatment of lung and brain cancer and precancerous conditions thereof.

  通过呼吸道给予的新化合物和其制药组合物，用于预防和/或治疗肺癌、脑癌及其癌前状态。
• COMPOUNDS AND COMPOSITIONS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER AND PRECANCEROUS CONDITIONS, INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER
  申请人：Medicon Pharmaceuticals, Inc.

  公开号：US20140121185A1

  公开（公告）日：2014-05-01

  Novel compounds and pharmaceutical compositions thereof for the treatment and/or prevention of cancer and precancerous conditions, inflammation-related disorders, pain and fever.
• COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER, SKIN DISORDERS, CANCER AND PRECANCEROUS CONDITIONS THEREOF
  申请人：Medicon Pharmaceuticals, Inc.

  公开号：US20140315834A1

  公开（公告）日：2014-10-23

  The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group. The moiety A is preferably an aliphatic, aromatic or alkylaryl group, preferably derived from a non-steroidal anti-inflammatory drug or NSAID (A). The moiety A is bound to a linker moiety (B) via the carboxyl of group A and a linking atom that is selected from oxygen, nitrogen, and sulphur, to form a carboxylic ester, and amide, or a thioester, bond (X 1 ) between groups A and B. Moiety B is a single bond, an aliphatic group, a substituted benzene, or an alkylene substituted hydrocarbon chain, which in turn is bound to functional moiety Z, which facilitates access of the compound into cells. The moiety Z can comprise, for example, a phosphorous-containing group, a nitrogen-containing group, or a folic acid residue.
• [EN] COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER, SKIN DISORDERS, CANCER AND PRECANCEROUS CONDITIONS THEREOF<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR UNE UTILISATION DANS LA PRÉVENTION ET LE TRAITEMENT DE TROUBLES ASSOCIÉS À L'INFLAMMATION, DE LA DOULEUR ET DE LA FIÈVRE, DE TROUBLES DE LA PEAU, DU CANCER ET D'ÉTATS PRÉCANCÉREUX DE CELUI-CI
  申请人：RIGAS BASIL

  公开号：WO2014047592A2

  公开（公告）日：2014-03-27

  The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti¬ platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group. The moiety A is preferably an aliphatic, aromatic or alkylaryl group, preferably derived from a non-steroidal anti-inflammatory drug or NSAID (A). The moiety A is bound to a linker moiety (B) via the carboxyl of group A and a linking atom that is selected from oxygen, nitrogen, and sulpher, to form a carboxylic ester, and amide, or a thioester, bond (X1) between groups A and B. Moiety B is a single bond, an aliphatic group, a substituted benzene, or an alkylene substituted hydrocarbon chain, which in turn is bound to functional moiety Z, which facilitates access of the compound into cells. The moiety Z can comprise, for example, a phosphorous-containing group, a nitrogen- containing group, or a folic acid residue.
• [EN] PHARMACEUTICAL DOSAGE FORMS CONTAINING N-[4-[[(2,4-DIAMINO-6-PTERIDINYL)METHYL] METHYLAMINO] BENZOYL]-L- GLUTAMIC ACID AND N-[4-[[(2-AMINO-3,4- DIHYDRO -4-OXO-6- PTERIDINYL) METHYL] METHYL AMINO] BENZOYL]-L-GLUTAMIC ACID<br/>[FR] FORMES GALÉNIQUES PHARMACEUTIQUES CONTENANT DE L'ACIDE N-[4-[[(2,4-DIAMINO-6-PTÉRIDINYL) MÉTHYL]MÉTHYLAMINO]BENZOYL]-L-GLUTAMIQUE ET DE L'ACIDE N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTÉRIDINYL)MÉTHYL]MÉTHYLAMINO]BENZOYL]-L-GLUTAMIQUE
  申请人：ONKO İLAÇ SANAYİ VE TİCARET A Ş

  公开号：WO2015183213A1

  公开（公告）日：2015-12-03

  The invention is related to solid, liquid, enteral and parenteral stable combinations of pharmaceutical forms comprising N- [4 - [[(2,4-Diamino-6-pteridinyl) methyl] methylamino] benzoyl] -L-glutamic acid and N- [4 - [[(2- Amino-3,4-dihydro-4-oxo-6- pteridinyl) methyl] methylamino] benzoyl] -L- glutamic acid pharmaceutically acceptable salts, particulary monohydrate, sodium and disodium, as active ingredients.